Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
18.42 USD | -1.55% | +3.14% | +27.74% |
09.04. | ORGANON & CO. : Morgan Stanley bekräftigt seine neutrale Bewertung | ZM |
08.04. | Shanghai Henlius Biotech Denosumab Biosimilar HLX14 erreicht Endpunkt | MT |
Kurzporträt
Mitarbeiterzahl: 10 000
Umsatz nach Geschäftsbereich
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Women's Health - Nexplanon/Implanon NXT
13,3
%
| 834 | 13,5 % | 830 | 13,3 % | -0.48% |
Cardiovascular - Atozet
8,3
%
| 457 | 7,4 % | 519 | 8,3 % | +13.57% |
Respiratory - Singulair
6,5
%
| 411 | 6,7 % | 404 | 6,5 % | -1.70% |
Other - Other
5,1
%
| 326 | 5,3 % | 319 | 5,1 % | -2.15% |
Cardiovascular - Zetia
4,9
%
| 357 | 5,8 % | 306 | 4,9 % | -14.29% |
Cardiovascular - Cozaar/Hyzaar
4,5
%
| 323 | 5,2 % | 281 | 4,5 % | -13.00% |
Biosimilars - Renflexis
4,4
%
| 226 | 3,7 % | 278 | 4,4 % | +23.01% |
Other Non-opioid Pain, Bone and Dermatology
4,4
%
| 273 | 4,4 % | 275 | 4,4 % | +0.73% |
Women's Health - Follistim AQ
4,2
%
| 229 | 3,7 % | 262 | 4,2 % | +14.41% |
Non-opioid Pain, Bone and Dermatology - Arcoxia
4,1
%
| 241 | 3,9 % | 257 | 4,1 % | +6.64% |
Respiratory - Nasonex
4,0
%
| 238 | 3,9 % | 253 | 4,0 % | +6.30% |
Respiratory - Dulera
3,1
%
| 180 | 2,9 % | 194 | 3,1 % | +7.78% |
Other Women's Health
2,7
%
| 204 | 3,3 % | 171 | 2,7 % | -16.18% |
Non-opioid Pain, Bone and Dermatology - Fosamax
2,5
%
| 152 | 2,5 % | 159 | 2,5 % | +4.61% |
Biosimilars - Ontruzant
2,5
%
| 122 | 2,0 % | 155 | 2,5 % | +27.05% |
Other Cardiovascular
2,5
%
| 159 | 2,6 % | 155 | 2,5 % | -2.52% |
Women's Health - NuvaRing
2,4
%
| 173 | 2,8 % | 152 | 2,4 % | -12.14% |
Respiratory - Clarinex
2,2
%
| 125 | 2,0 % | 136 | 2,2 % | +8.80% |
Women's Health - Marvelon/Mercilon
2,1
%
| 110 | 1,8 % | 134 | 2,1 % | +21.82% |
Cardiovascular - Vytorin
2,1
%
| 130 | 2,1 % | 129 | 2,1 % | -0.77% |
Other - Propecia
2,0
%
| 125 | 2,0 % | 125 | 2,0 % | 0.00% |
Other
1,9
%
| 146 | 2,4 % | 121 | 1,9 % | -17.12% |
Women's Health - Ganirelix Acetate Injection
1,8
%
| 123 | 2,0 % | 110 | 1,8 % | -10.57% |
Other - Proscar
1,5
%
| 101 | 1,6 % | 97 | 1,5 % | -3.96% |
Non-opioid Pain, Bone and Dermatology - Diprospan
1,5
%
| 122 | 2,0 % | 91 | 1,5 % | -25.41% |
Other Respiratory
1,2
%
| 83 | 1,3 % | 77 | 1,2 % | -7.23% |
Biosimilars - Brenzys
1,2
%
| 75 | 1,2 % | 73 | 1,2 % | -2.67% |
Cardiovascular - Rosuzet
1,1
%
| 71 | 1,1 % | 70 | 1,1 % | -1.41% |
Biosimilars - Hadlima
0,7
%
| 19 | 0,3 % | 44 | 0,7 % | +131.58% |
Women's Health - Jada
0,7
%
| - | - | 43 | 0,7 % | - |
Biosimilars - Aybintio
0,7
%
| 39 | 0,6 % | 43 | 0,7 % | +10.26% |
Umsatz je Region
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Europe and Canada
26,7
%
| 1 631 | 26,4 % | 1 673 | 26,7 % | +2.58% |
United States
23,6
%
| 1 437 | 23,3 % | 1 478 | 23,6 % | +2.85% |
Asia Pacific and Japan
18,0
%
| 1 143 | 18,5 % | 1 129 | 18,0 % | -1.22% |
Latin America, Middle East, Russia and Africa
15,4
%
| 895 | 14,5 % | 965 | 15,4 % | +7.82% |
China
13,8
%
| 917 | 14,9 % | 864 | 13,8 % | -5.78% |
Global
2,5
%
| 151 | 2,4 % | 154 | 2,5 % | +1.99% |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Kevin Ali
CEO | Chief Executive Officer | 63 | 02.06.21 |
Matthew Walsh
DFI | Director of Finance/CFO | 57 | 02.06.21 |
Chief Tech/Sci/R&D Officer | 54 | 05.09.23 | |
Rachel Stahler
CTO | Chief Tech/Sci/R&D Officer | 48 | 01.01.21 |
Marcel van Duin
CTO | Chief Tech/Sci/R&D Officer | - | 01.11.22 |
Jennifer Halchak
IRC | Investor Relations Contact | - | - |
Charlotte Owens
PRN | Corporate Officer/Principal | - | 05.09.23 |
Kirke Weaver
LAW | General Counsel | - | 01.07.22 |
Vittorio Nisita
PRN | Corporate Officer/Principal | 56 | 02.06.21 |
Joseph Morrissey
PRN | Corporate Officer/Principal | 59 | 02.06.21 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Rochelle Lazarus
BRD | Director/Board Member | 76 | 02.06.21 |
Carrie Cox
CHM | Chairman | 66 | 02.06.21 |
Robert Essner
BRD | Director/Board Member | 76 | 02.06.21 |
Helene Gayle
BRD | Director/Board Member | 69 | 02.06.21 |
Shalini Sharp
BRD | Director/Board Member | 49 | 02.06.21 |
Director/Board Member | 70 | 02.06.21 | |
Philip Ozuah
BRD | Director/Board Member | 61 | 02.06.21 |
Grace Whiteford
BRD | Director/Board Member | 61 | 02.06.21 |
Director/Board Member | 55 | 02.06.21 | |
Kevin Ali
CEO | Chief Executive Officer | 63 | 02.06.21 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 255 638 256 | 255 270 098 ( 99,86 %) | 0 | 99,86 % |
Unternehmenskontakt
Konzerngesellschaften
Name | Kategorie und Branche |
---|---|
Pharmaceuticals: Major
| |
Organon (India) Pvt Ltd.
Organon (India) Pvt Ltd. Pharmaceuticals: MajorHealth Technology Organon India Pvt Ltd. manufactures and distribution of pharmaceutical preparations. The company is headquartered in Mumbai, India. |
Pharmaceuticals: Major
|
Dashtag
Dashtag Financial ConglomeratesFinance Founded in 1906, Dashtag is a part of Organon & Co. and operates an investment holding British company. The private company is based in Hoddesdon, UK. |
Financial Conglomerates
|
GTS FI BV
GTS FI BV Financial ConglomeratesFinance Part of Organon & Co., GTS FI BV is an investment holding Dutch company that provides financing services. The private company is located in Netherlands. |
Financial Conglomerates
|
Organon Finance 1 LLC
|
Finance/Rental/Leasing
|
Organon LLC
| |
Organon Foreign Debt Co-Issuer BV
|
Sektor
Umsatz nach Geschäftsbereich
Umsatz je Region
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+27.74% | 4.78 Mrd. | |
+24.17% | 562 Mrd. | |
-6.33% | 358 Mrd. | |
+19.90% | 322 Mrd. | |
+7.95% | 297 Mrd. | |
+13.45% | 219 Mrd. | |
+6.04% | 199 Mrd. | |
-10.51% | 196 Mrd. | |
-12.26% | 149 Mrd. | |
-6.47% | 146 Mrd. |
- Börse
- Aktien
- A3CPKP Aktie
- Unternehmen Organon & Co.